{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:15:26Z","timestamp":1787030126842,"version":"build-2736575974"},"reference-count":234,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Recent cancer immunotherapy breakthroughs have fundamentally changed oncology and revived the fading hope for a cancer cure. The immune checkpoint inhibitors (ICI) became an indispensable tool for the treatment of many malignant tumors. Alongside ICI, the application of oncolytic viruses in clinical trials is demonstrating encouraging outcomes. Dozens of combinations of oncolytic viruses with conventional radiotherapy and chemotherapy are widely used or studied, but it seems quite complicated to highlight the most effective combinations. Our review summarizes the results of clinical trials evaluating oncolytic viruses with or without genetic alterations in combination with immune checkpoint blockade, cytokines, antigens and other oncolytic viruses as well. This review is focused on the efficacy and safety of virotherapy and the most promising combinations based on the published clinical data, rather than presenting all oncolytic virus variations, which are discussed in comprehensive literature reviews. We briefly revise the research landscape of oncolytic viruses and discuss future perspectives in virus immunotherapy, in order to provide an insight for novel strategies of cancer treatment.<\/jats:p>","DOI":"10.3390\/v13071271","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T22:39:43Z","timestamp":1625006383000},"page":"1271","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes"],"prefix":"10.3390","volume":"13","author":[{"given":"Alexander","family":"Malogolovkin","sequence":"first","affiliation":[{"name":"Gene Therapy Department, Sirius University of Science and Technology, Olympic Avenue, 1, 354340 Sochi, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizami","family":"Gasanov","sequence":"additional","affiliation":[{"name":"Gene Therapy Department, Sirius University of Science and Technology, Olympic Avenue, 1, 354340 Sochi, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5953-8097","authenticated-orcid":false,"given":"Alexander","family":"Egorov","sequence":"additional","affiliation":[{"name":"Gene Therapy Department, Sirius University of Science and Technology, Olympic Avenue, 1, 354340 Sochi, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Weener","sequence":"additional","affiliation":[{"name":"Gene Therapy Department, Sirius University of Science and Technology, Olympic Avenue, 1, 354340 Sochi, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9573-4183","authenticated-orcid":false,"given":"Roman","family":"Ivanov","sequence":"additional","affiliation":[{"name":"Gene Therapy Department, Sirius University of Science and Technology, Olympic Avenue, 1, 354340 Sochi, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6391-5182","authenticated-orcid":false,"given":"Alexander","family":"Karabelsky","sequence":"additional","affiliation":[{"name":"Gene Therapy Department, Sirius University of Science and Technology, Olympic Avenue, 1, 354340 Sochi, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"key":"ref_1","unstructured":"Williams, J. (2019). The Immunotherapy Revolution: The Best New Hope for Saving Cancer Patients, Williams Cancer Institute."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Farkona, S., Diamandis, E.P., and Blasutig, I.M. (2016). Cancer immunotherapy: The beginning of the end of cancer?. BMC Med., 14.","DOI":"10.1186\/s12916-016-0623-5"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ctrv.2017.01.008","article-title":"The expanding role of immunotherapy","volume":"54","author":"Hierro","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"xxiii","DOI":"10.1016\/S0076-6879(20)30020-3","article-title":"Preface: More than two decades of modern tumor immunology","volume":"631","author":"Galluzzi","year":"2020","journal-title":"Methods Enzymol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ymthe.2018.03.007","article-title":"The Immune System in Oncolytic Immunovirotherapy: Gospel, Schism and Heresy","volume":"26","author":"Vile","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00262-015-1727-z","article-title":"Intratumoral immunotherapy for melanoma","volume":"64","author":"Singh","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2217\/imt.10.6","article-title":"New perspectives in cancer virotherapy: Bringing the immune system into play","volume":"2","author":"Boisgerault","year":"2010","journal-title":"Immunotherapy"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1517\/14712598.2015.1044433","article-title":"Arming oncolytic viruses to leverage antitumor immunity","volume":"15","author":"Janssen","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_9","first-page":"222","article-title":"Vaccine Therapies Against Gliomas: Prime Time Yet?","volume":"30","author":"Puduvalli","year":"2016","journal-title":"Oncology"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ahmad, A., Uddin, S., and Steinhoff, M. (2020). CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113906"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd.2015.35","article-title":"Development of immuno-oncology drugs-from CTLA4 to PD1 to the next generations","volume":"15","author":"Hoos","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.01.035","article-title":"Viral therapy for pancreatic cancer: Tackle the bad guys with poison","volume":"333","author":"Xu","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41417-018-0042-1","article-title":"Turning cold tumours hot: Oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference","volume":"26","author":"Dyer","year":"2019","journal-title":"Cancer Gene Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/mt.2011.26","article-title":"Targeting tumor vasculature with an oncolytic virus","volume":"19","author":"Breitbach","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.coviro.2015.03.020","article-title":"Oncolytic viruses: Perspectives on clinical development","volume":"13","author":"Burke","year":"2015","journal-title":"Curr. Opin. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Eissa, I.R., Bustos-Villalobos, I., Ichinose, T., Matsumura, S., Naoe, Y., Miyajima, N., Morimoto, D., Mukoyama, N., Zhiwen, W., and Tanaka, M. (2018). The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers. Cancers, 10.","DOI":"10.3390\/cancers10100356"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1634\/theoncologist.2019-0438","article-title":"Intratumoral Immunotherapy-Update 2019","volume":"25","author":"Hamid","year":"2020","journal-title":"Oncologist"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e001486","DOI":"10.1136\/jitc-2020-001486","article-title":"Clinical landscape of oncolytic virus research in 2020","volume":"8","author":"Macedo","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Cook, M., and Chauhan, A. (2020). Clinical application of oncolytic viruses: A systematic review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207505"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/pcmedi\/pby011","article-title":"Recent updates on cancer immunotherapy","volume":"1","author":"Liu","year":"2018","journal-title":"Precis. Clin. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1172\/JCI120303","article-title":"Unleashing the therapeutic potential of oncolytic viruses","volume":"128","author":"Bommareddy","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.4161\/cc.8.14.8934","article-title":"Hypoxia enhances the replication of oncolytic herpes simplex virus in p53- breast cancer cells","volume":"8","author":"Fasullo","year":"2009","journal-title":"Cell Cycle"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/fmb.12.4","article-title":"Oncolytic Newcastle disease virus for cancer therapy: Old challenges and new directions","volume":"7","author":"Zamarin","year":"2012","journal-title":"Future Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e000337","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1128\/JVI.02213-08","article-title":"Activated Ras\/MEK Inhibits the Antiviral Response of Alpha Interferon by Reducing STAT2 Levels","volume":"83","author":"Christian","year":"2009","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e01643-19","DOI":"10.1128\/JVI.01643-19","article-title":"Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells","volume":"94","author":"Seegers","year":"2020","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/mt.2009.231","article-title":"Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma","volume":"18","author":"Altomonte","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1006\/viro.1998.9535","article-title":"Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion","volume":"254","author":"Kahn","year":"1999","journal-title":"Virology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1128\/JVI.02040-09","article-title":"Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells","volume":"84","author":"Wollmann","year":"2010","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/mt.2008.143","article-title":"The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and aanti-HBV activities in patients with hepatocellular carcinoma","volume":"16","author":"Liu","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1158\/0008-5472.CAN-12-2687","article-title":"Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans","volume":"73","author":"Breitbach","year":"2013","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/OV.S38901","article-title":"Oncolytic virus therapy for cancer","volume":"31","author":"Kaufman","year":"2013","journal-title":"Oncolytic Virother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1158\/0008-5472.CAN-06-3974","article-title":"Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus","volume":"67","author":"Diaz","year":"2007","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7358","DOI":"10.1158\/1078-0432.CCR-08-0831","article-title":"Tumor infection by oncolytic reovirus primes adaptive antitumor immunity","volume":"14","author":"Prestwich","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1158\/0008-5472.CAN-09-4658","article-title":"Type II IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer","volume":"70","author":"Wongthida","year":"2010","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/mt.2010.264","article-title":"Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy","volume":"19","author":"Sobol","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/mt.2011.265","article-title":"Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells","volume":"20","author":"Fu","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1387\/ijdb.150061pa","article-title":"Immunogenic cell death","volume":"59","author":"Garg","year":"2015","journal-title":"Int. J. Dev. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1517\/17425247.2014.874414","article-title":"Utilizing adenovirus vectors for gene delivery in cancer","volume":"11","author":"Kasala","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1517\/14728222.2012.712962","article-title":"Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets","volume":"16","author":"Portella","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-12-16","article-title":"Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: A randomized clinical trial","volume":"12","author":"Li","year":"2014","journal-title":"BMC Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.18632\/oncotarget.2901","article-title":"Immunological data from cancer patients treated with Ad5\/3-E2F-\u039424-GMCSF suggests utility for tumor immunotherapy","volume":"6","author":"Hemminki","year":"2015","journal-title":"Oncotarget"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Dreno, B., Urosevic-Maiwald, M., Kim, Y., Guitart, J., Duvic, M., Dereure, O., Khammari, A., Knol, A.-C., Derbij, A., and Lusky, M. (2014). TG1042 (Adenovirus-interferon-\u03b3) in Primary Cutaneous B-cell Lymphomas: A Phase II Clinical Trial. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0083670"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s12032-014-0095-4","article-title":"Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5","volume":"31","author":"Dong","year":"2014","journal-title":"Med. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00432-009-0701-6","article-title":"Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma","volume":"136","author":"Yang","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S1470-2045(13)70274-2","article-title":"Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): A randomised, open-label, phase 3 trial","volume":"14","author":"Westphal","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1177\/1947601912437933","article-title":"Antitumor Activity of VB-111, a Novel Antiangiogenic Virotherapeutic, in Thyroid Cancer Xenograft Mouse Models","volume":"2","author":"Reddi","year":"2011","journal-title":"Genes Ther. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ygyno.2020.02.034","article-title":"Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I\/II study are associated with an immunotherapeutic effect","volume":"157","author":"Arend","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5732\/cjc.009.10149","article-title":"Clinical research on recombinant human Ad-p53 injection combined with cisplatin in treatment of malignant pleural effusion induced by lung cancer","volume":"28","author":"Zhao","year":"2009","journal-title":"Chin. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/CAD.0000000000000448","article-title":"Efficacy and safety of recombinant human adenovirus p53 combined with chemoradiotherapy in the treatment of recurrent nasopharyngeal carcinoma","volume":"28","author":"Ma","year":"2016","journal-title":"Anticancer Drugs"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.3892\/ol.2017.5901","article-title":"Efficacy of recombinant human adenovirus-p53 combined with chemotherapy for locally advanced cervical cancer: A clinical trial","volume":"13","author":"Xiao","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/neuros\/nyx507","article-title":"Phase i Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients","volume":"83","author":"Tejada","year":"2018","journal-title":"Clin. Neurosurg."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.3892\/ol.2015.3054","article-title":"Efficacy of recombinant adenoviral human p53 gene in the treatment of lung cancer-mediated pleural effusion","volume":"9","author":"Li","year":"2015","journal-title":"Oncol. Lett."},{"key":"ref_55","first-page":"709","article-title":"Treatment of recurrent malignant gliomas by surgery combined with recombinant adenovirus-p53","volume":"32","author":"Zhu","year":"2010","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Hosmani, J., Mushtaq, S., Abullais, S.S., Almubarak, H.M., Assiri, K., Testarelli, L., Mazzoni, A., and Patil, S. (2021). Recombinant Human Adenovirus-p53 Therapy for the Treatment of Oral Leukoplakia and Oral Squamous Cell Carcinoma: A Systematic Review. Medicina, 57.","DOI":"10.3390\/medicina57050438"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine, the World First Oncolytic Virus Medicine and its Update in China","volume":"18","author":"Liang","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2001.19.2.289","article-title":"Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer","volume":"19","author":"Nemunaitis","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13014-020-01593-5","article-title":"A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR)","volume":"15","author":"Davis","year":"2020","journal-title":"Radiat. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40425-019-0510-7","article-title":"A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)","volume":"7","author":"Machiels","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.vetmic.2010.02.014","article-title":"Herpesvirus systematics","volume":"143","author":"Davison","year":"2010","journal-title":"Vet. Microbiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1126\/science.1851332","article-title":"Experimental Therapy of Human Glioma by Means of","volume":"252","author":"Martuza","year":"1991","journal-title":"Science"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/ijc.23030","article-title":"Herpes oncolytic therapy of salivary gland carcinomas","volume":"122","author":"Reid","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"7802","DOI":"10.1038\/sj.onc.1209037","article-title":"Oncolytic viral therapies\u2014The clinical experience","volume":"24","author":"Aghi","year":"2005","journal-title":"Oncogene"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/mt.2008.49","article-title":"Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide","volume":"16","author":"Currier","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_66","unstructured":"World Health Organization (2021, May 10). Herpes Simplex Virus. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/herpes-simplex-virus."},{"key":"ref_67","first-page":"1","article-title":"Oncolytic herpes simplex virus and immunotherapy 11 Medical and Health Sciences 1108 Medical Microbiology","volume":"19","author":"Ma","year":"2018","journal-title":"BMC Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-016-0238-9","article-title":"Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma","volume":"18","author":"Bommareddy","year":"2017","journal-title":"Am. J. Clin. Dermatol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/hed.24522","article-title":"Cutaneous head and neck melanoma in OPTiM, a randomized pha se 3 trial oftalimogene laherparepvec versus granulocyte-macrophage colony-stimulatingfactor for the treatment of unresected stage IIIB\/I IIC\/IV melanoma","volume":"38","author":"Andtbacka","year":"2016","journal-title":"Head Neck"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e001701","DOI":"10.1136\/jitc-2020-001701","article-title":"Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany","volume":"9","author":"Ressler","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination with Ipilimumab Versus Ipilimumab Alone in Patients with Advanced, Unresectable Melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s40425-019-0682-1","article-title":"Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1","volume":"7","author":"Thomas","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e22050","DOI":"10.1200\/JCO.2020.38.15_suppl.e22050","article-title":"An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts","volume":"38","author":"Middleton","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3389\/fonc.2017.00096","article-title":"Genetically Engineered Vaccinia Viruses as Agents for Cancer Treatment, Imaging, and Transgene Delivery","volume":"7","author":"Haddad","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2217\/imt.15.90","article-title":"Vaccinia virus, a promising new therapeutic agent for pancreatic cancer","volume":"7","author":"Yaghchi","year":"2015","journal-title":"Immunotherapy"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/14712598.2019.1600669","article-title":"Poxvirus oncolytic virotherapy","volume":"19","author":"McFadden","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0022-5347(05)65755-2","article-title":"Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer","volume":"166","author":"Gomella","year":"2001","journal-title":"J. Urol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12967-019-2011-3","article-title":"First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells","volume":"17","author":"Minev","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/mt.2014.194","article-title":"First-in-man study of western reserve strain oncolytic vaccinia virus: Safety, systemic spread, and antitumor activity","volume":"23","author":"Zeh","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/mt.2016.101","article-title":"Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients with Advanced Solid Cancers","volume":"24","author":"Guo","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-18-0244","article-title":"Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis","volume":"24","author":"Lauer","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-16-3232","article-title":"Phase I trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma","volume":"23","author":"Mell","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1615817","DOI":"10.1080\/2162402X.2019.1615817","article-title":"Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: A randomized multicenter Phase IIb trial (TRAVERSE)","volume":"8","author":"Moehler","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.2018.36.6_suppl.671","article-title":"Phase II trial of pexa-vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, in patients with metastatic, refractory renal cell carcinoma (RCC)","volume":"36","author":"Kim","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"v496","DOI":"10.1093\/annonc\/mdz253.039","article-title":"Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumour immunity","volume":"30","author":"Samson","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"6846","DOI":"10.1158\/1078-0432.CCR-17-1087","article-title":"Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury","volume":"23","author":"Heery","year":"2017","journal-title":"Clin Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00705-019-04520-6","article-title":"Recommendations for the nomenclature of enteroviruses and rhinoviruses","volume":"165","author":"Simmonds","year":"2020","journal-title":"Arch. Virol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1158\/1078-0432.CCR-18-4022","article-title":"Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer","volume":"25","author":"Annels","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/CMR.0000000000000180","article-title":"Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study","volume":"25","author":"Proboka","year":"2015","journal-title":"Melanoma Res."},{"key":"ref_92","unstructured":"Voroshilova, M. (1988). Virological and immunological aspects of administration of live enteroviral vaccines in oncological disease. Poleznye Dlya Ogranizma Nepatogennye Shtammy Enterovirusov: Profilakticheskoe i Lechebnoe ikh Primenenie (Useful Nonpathogenic Enterovirus Strains: Preventive and Therapeutic Applications), Meditsina."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"79828","DOI":"10.18632\/oncotarget.12975","article-title":"Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models","volume":"7","author":"Holl","year":"2016","journal-title":"Oncotarget"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1158\/1078-0432.CCR-05-1595","article-title":"Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus","volume":"12","author":"Ochiai","year":"2006","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/OV.S56322","article-title":"Applications of coxsackievirus A21 in oncology","volume":"3","author":"Bradley","year":"2014","journal-title":"Oncolytic Virother."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1743-422X-8-22","article-title":"Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18","volume":"8","author":"Au","year":"2011","journal-title":"Virol. J."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Hwang, J.K., Hong, J., and Yun, C.-O. (2020). Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228627"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/0002-9343(49)90130-8","article-title":"Histopathologic basis of clinical findings in poliomyelitis","volume":"6","author":"Bodian","year":"1949","journal-title":"Am. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent Glioblastoma Treated with Recombinant Poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1073\/pnas.68.4.836","article-title":"Viruses as an Aid to Cancer Therapy: Regression of Solid and Ascites Tumors in Rodents After Treatment with Bovine Enterovirus","volume":"68","author":"Taylor","year":"1971","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_101","unstructured":"Voroshilova, M. (1979). Enterovirusnyye Infektsii Cheloveka (Human Enteroviral Infections), Meditsina."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF01317504","article-title":"Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria","volume":"60","author":"Chumakov","year":"1979","journal-title":"Arch. Virol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1134\/S0026893312050032","article-title":"Oncolytic enteroviruses","volume":"46","author":"Chumakov","year":"2012","journal-title":"Mol. Biol."},{"key":"ref_104","first-page":"269","article-title":"Studies on biological and morphological properties of viruses ECHO1 and ECHO12","volume":"XIV","author":"Voroshilova","year":"1970","journal-title":"Tr. Inst. Poliom. Virus. Entsef. Akad. Med. Nauk SSSR"},{"key":"ref_105","unstructured":"Voroshilova, M., and Baganova, N. (1969). Experience in treating patients with gastrointestinal tumors by live enterovirus vaccines. Virusnyi Onkoliz i Iskusstvennaya Geterogenizatsiya Opukholei (Viral Oncolysis and Artificial Heterogenization of Tumors)."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Soboleva, A., Lipatova, A., Kochetkov, D., and Chumakov, P. (2018). Changes in the sensitivity of human glioblastoma cells to oncolytic enteroviruses induced by passaging. Bull. RSMU, 37\u201341.","DOI":"10.24075\/brsmu.2018.025"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Sidorenko, A., Zheltukhin, A., Le, T., Soboleva, A., Lipatova, A., Golbin, D., and Chumakov, P. (2018). Persistence of oncolytic Coxsackie virus A7 in subcutaneous human glioblastoma xenografts in mice in the context of experimental therapy. Bull. RSMU, 41\u201346.","DOI":"10.24075\/brsmu.2018.032"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Zheltukhin, A., Soboleva, A., Sosnovtseva, A., Le, T., Ilyinskaya, G., Kochetkov, D., Lipatova, A., and Chumakov, P. (2018). Human enteroviruses exhibit selective oncolytic activity in the model of human glioblastoma multiforme xenografts in immunodeficient mice. Bull. RSMU, 42\u201348.","DOI":"10.24075\/brsmu.2018.026\/translation"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.omto.2021.03.013","article-title":"Efficient delivery of oncolytic enterovirus by carrier cell line NK-92","volume":"21","author":"Podshivalova","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejphar.2018.08.042","article-title":"The advent of oncolytic virotherapy in oncology: The Rigvir\u00ae story","volume":"837","author":"Alberts","year":"2018","journal-title":"Eur. J. Pharm. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/ccr3.2928","article-title":"Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir(\u00ae) therapy: A case report","volume":"8","author":"Pumpure","year":"2020","journal-title":"Clin. Case Rep."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"100615","DOI":"10.1016\/j.ajoc.2020.100615","article-title":"ECHO-7 oncolytic virus Rigvir\u00ae in an adjuvant setting for stage I uveal melanoma; A retrospective case report","volume":"17","author":"Jaunalksne","year":"2020","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/OV.S100072","article-title":"Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma","volume":"6","author":"Babiker","year":"2017","journal-title":"Oncolytic Virother."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e17883","DOI":"10.1097\/MD.0000000000017883","article-title":"Treatment of a stage III rima glottidis patient with the oncolytic virus Rigvir: A retrospective case report","volume":"98","author":"Proboka","year":"2019","journal-title":"Medicine"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e002203","DOI":"10.1136\/jitc-2020-002203","article-title":"Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma","volume":"9","author":"Beasley","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1089\/hum.1998.9.13-1909","article-title":"New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses","volume":"9","author":"Fallaux","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jtho.2019.09.083","article-title":"A Randomized Double-Blind Phase II Study of the Seneca Valley Virus ( NTX-010 ) versus Placebo for Patients with Extensive-Stage SCLC ( ES SCLC ) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cance","volume":"15","author":"Schenk","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1099\/jgv.0.001328","article-title":"ICTV Virus Taxonomy Profile: Paramyxoviridae","volume":"100","author":"Rima","year":"2019","journal-title":"J. Gen. Virol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/jnci\/86.16.1228","article-title":"Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy","volume":"86","author":"Lorence","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/clpt.2010.211","article-title":"Therapeutic potential of oncolytic measles virus: Promises and challenges","volume":"88","author":"Galanis","year":"2010","journal-title":"Clin. Pharm. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/sj.cgt.7700948","article-title":"Pharmacokinetics of oncolytic measles virotherapy: Eventual equilibrium between virus and tumor in an ovarian cancer xenograft model","volume":"13","author":"Peng","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/mt.2009.218","article-title":"Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter","volume":"17","author":"Msaouel","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1386-6532(99)00072-4","article-title":"Newcastle disease virus (NDV): Brief history of its oncolytic strains","volume":"16","author":"Sinkovics","year":"2000","journal-title":"J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF02987752","article-title":"A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate","volume":"9","author":"Cassel","year":"1992","journal-title":"Med. Oncol. Tumor Pharm. Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/BF03401771","article-title":"A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire","volume":"4","author":"Batliwalla","year":"1998","journal-title":"Mol. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF00184874","article-title":"Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines","volume":"13","author":"Kirchner","year":"1995","journal-title":"World J. Urol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1200\/JCO.1997.15.4.1354","article-title":"Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer","volume":"15","author":"Ahlert","year":"1997","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_128","first-page":"21","article-title":"Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma","volume":"2","author":"Ockert","year":"1996","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Schirrmacher, V. (2016). Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!. Biomedicines, 4.","DOI":"10.3390\/biomedicines4030016"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Burman, B., Pesci, G., and Zamarin, D. (2020). Newcastle Disease Virus at the Forefront of Cancer Immunotherapy. Cancers, 12.","DOI":"10.3390\/cancers12123552"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.7150\/ijms.59185","article-title":"Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus","volume":"18","author":"Meng","year":"2021","journal-title":"Int. J. Med. Sci."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/1097-0142(196507)18:7<863::AID-CNCR2820180714>3.0.CO;2-V","article-title":"Newcastle disease virus as an antineoplastic agent","volume":"18","author":"Cassel","year":"1965","journal-title":"Cancer"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ymthe.2005.08.016","article-title":"Phase I\/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme","volume":"13","author":"Freeman","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2002.08.042","article-title":"Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers","volume":"20","author":"Pecora","year":"2002","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/B:NEON.0000021735.85511.05","article-title":"MTH-68\/H oncolytic viral treatment in human high-grade gliomas","volume":"67","author":"Csatary","year":"2004","journal-title":"J. Neurooncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0065-230X(08)60899-4","article-title":"Viral xenogenization of intact tumor cells","volume":"30","author":"Kobayashi","year":"1979","journal-title":"Adv. Cancer Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/ijc.2910370416","article-title":"Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects","volume":"37","author":"Heicappell","year":"1986","journal-title":"Int. J. Cancer"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF00058060","article-title":"Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity","volume":"5","author":"Schirrmacher","year":"1987","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/eji.1830180803","article-title":"Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response","volume":"18","author":"Weber","year":"1988","journal-title":"Eur. J. Immunol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/BF00205796","article-title":"Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation","volume":"28","author":"Schild","year":"1989","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/0008-8749(90)90302-8","article-title":"Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha\/beta","volume":"126","author":"Zawatzky","year":"1990","journal-title":"Cell. Immunol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"8057","DOI":"10.1158\/0008-5472.CAN-04-1545","article-title":"Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells","volume":"64","author":"Karcher","year":"2004","journal-title":"Cancer Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1200\/JCO.2004.09.038","article-title":"Antitumor vaccination of patients with glioblastoma multiforme: A pilot study to assess feasibility, safety, and clinical benefit","volume":"22","author":"Steiner","year":"2004","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1586\/14760584.2014.854169","article-title":"Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: Long-term patient survival and mechanism of function","volume":"13","author":"Schirrmacher","year":"2014","journal-title":"Expert Rev. Vaccines"},{"key":"ref_145","first-page":"947","article-title":"Tumor Response and 4 year survival-data of patients with advanced renal-cell carcinoma treated with autologous tumor vaccine and subcutaneous R-Il-2 And Ifn-Alpha(2b)","volume":"6","author":"Pomer","year":"1995","journal-title":"Int. J. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1182\/blood-2004-11-4558","article-title":"Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells","volume":"106","author":"Heinzerling","year":"2005","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"15017","DOI":"10.1038\/mto.2015.17","article-title":"Oncolysis by paramyxoviruses: Preclinical and clinical studies","volume":"2","author":"Matveeva","year":"2015","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1134\/S0026893317010046","article-title":"Biomarkers of prostate cancer sensitivity to the Sendai virus","volume":"51","author":"Belova","year":"2017","journal-title":"Mol. Biol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e00818-16","DOI":"10.1128\/genomeA.00818-16","article-title":"V Complete Genome Sequence of the Oncolytic Sendai virus Strain Moscow","volume":"4","author":"Zainutdinov","year":"2016","journal-title":"Genome Announc."},{"key":"ref_150","unstructured":"Senin, V.M., and Matveeva, O.V.S.A.V. (2014). Method for cancer immunotherapy and pharmaceutical compositions based on oncolytic non-pathogenic sendai virus. (9526779B2), US Patent."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1517\/14712598.4.10.1685","article-title":"Oncolytic measles viruses for cancer therapy","volume":"4","author":"Nakamura","year":"2004","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2174\/156652308784746459","article-title":"Measles virus as an oncolytic vector platform","volume":"8","author":"Blechacz","year":"2008","journal-title":"Curr. Gene Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/0008-5472.CAN-09-2762","article-title":"Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer","volume":"70","author":"Galanis","year":"2010","journal-title":"Cancer Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/0008-5472.CAN-14-2533","article-title":"Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer","volume":"75","author":"Galanis","year":"2015","journal-title":"Cancer Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1038\/leu.2017.120","article-title":"Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma","volume":"31","author":"Dispenzieri","year":"2017","journal-title":"Leukemia"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/nar\/gks1220","article-title":"ViralZone: Recent updates to the virus knowledge resource","volume":"41","author":"Masson","year":"2013","journal-title":"Nucleic Acid Res."},{"key":"ref_157","unstructured":"Wagner, R.R. (1987). Rhabdovirus Genomes and Their Products BT-The Rhabdoviruses, Springer US."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.molcel.2004.11.023","article-title":"VSV disrupts the Rae1\/mrnp41 mRNA nuclear export pathway","volume":"17","author":"Faria","year":"2005","journal-title":"Mol. Cell"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"53.e5","DOI":"10.1016\/j.celrep.2019.12.024","article-title":"Structure of the Vesicular Stomatitis Virus L Protein in Complex with Its Phosphoprotein Cofactor","volume":"30","author":"Jenni","year":"2020","journal-title":"Cell Rep."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"14628","DOI":"10.1073\/pnas.1209147109","article-title":"Critical phosphoprotein elements that regulate polymerase architecture and function in vesicular stomatitis virus","volume":"109","author":"Rahmeh","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"9961","DOI":"10.1074\/jbc.M113.542761","article-title":"Sensitivity of the polymerase of vesicular stomatitis virus to 2\u2019 substitutions in the template and nucleotide triphosphate during initiation and elongation","volume":"289","author":"Morin","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/infdis\/jir349","article-title":"Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections","volume":"204","author":"Geisbert","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/02648725.2018.1474320","article-title":"Rhabdoviruses as vaccine platforms for infectious disease and cancer","volume":"34","author":"Zemp","year":"2018","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1089\/humc.2017.015","article-title":"Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV","volume":"28","author":"Naik","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_165","unstructured":"(2021, May 10). Prioritizing diseases for research and development in emergency contexts. Available online: https:\/\/www.who.int\/activities\/prioritizing-diseases-for-research-and-development-in-emergency-contexts."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1080\/21645515.2019.1649532","article-title":"Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens","volume":"15","author":"Fathi","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1099\/jgv.0.000980","article-title":"Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: A 5-year update","volume":"98","author":"Felt","year":"2017","journal-title":"J. Gen. Virol."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Bishnoi, S., Tiwari, R., Gupta, S., Byrareddy, S.N., and Nayak, D. (2018). Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy. Viruses, 10.","DOI":"10.3390\/v10020090"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"7713","DOI":"10.1158\/0008-5472.CAN-09-1013","article-title":"Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma","volume":"69","author":"Willmon","year":"2009","journal-title":"Cancer Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.virol.2005.01.009","article-title":"VSV replication in neurons is inhibited by type I IFN at multiple stages of infection","volume":"333","author":"Trottier","year":"2005","journal-title":"Virology"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1200\/JCO.2020.38.15_suppl.3090","article-title":"Relationship of infusion duration to safety, efficacy, and pharmacodynamics (PD): Second part of a phase I-II study using VSV-IFN\u03b2-NIS (VV1) oncolytic virus in patients with refractory solid tumors","volume":"38","author":"Merchan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"CT072","DOI":"10.1158\/1538-7445.AM2018-CT072","article-title":"Abstract CT072: First in human (FIH) dose escalation studies of intravenous administration of VSV-IFN\u03b2-NIS (Voyager-V1\u2122) in Stage IV or recurrent endometrial cancer","volume":"78","author":"Block","year":"2018","journal-title":"Cancer Res."},{"key":"ref_173","unstructured":"(2021, May 12). Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Available online: https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper140853.html."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.3892\/ol.2016.4280","article-title":"Differential expression of TYRP1 in adult human retinal pigment epithelium and uveal melanoma cells","volume":"11","author":"Qiu","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1038\/mt.2014.134","article-title":"The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor\u2019s anatomical site","volume":"22","author":"Rajani","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nbt.2157","article-title":"Articles Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma","volume":"30","author":"Pulido","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2217\/fon-2020-0823","article-title":"Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma","volume":"17","author":"Keeping","year":"2021","journal-title":"Futur. Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/1750743X.1.1.19","article-title":"MAGE A3 antigen-specific cancer immunotherapeutic","volume":"1","author":"Peled","year":"2009","journal-title":"Immunotherapy"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.3389\/fmicb.2019.03116","article-title":"Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy","volume":"10","author":"Pal","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1089\/hum.2005.16.996","article-title":"Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells","volume":"16","author":"Moehler","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cytogfr.2010.02.011","article-title":"Oncolytic parvoviruses as cancer therapeutics","volume":"21","author":"Rommelaere","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/ijc.25415","article-title":"Enhancement of NK cell antitumor responses using an oncolytic parvovirus","volume":"128","author":"Bhat","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1439-0450.2005.00877.x","article-title":"Oncolytic potential of rodent parvoviruses for cancer therapy in humans: A brief review","volume":"52","author":"Geletneky","year":"2005","journal-title":"J. Vet. Med. B. Infect. Dis. Vet. Public Health"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1016\/j.ymthe.2017.08.016","article-title":"Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I\/IIa Glioblastoma Trial","volume":"25","author":"Geletneky","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1007\/s00705-019-04306-w","article-title":"Changes to virus taxonomy and the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2019)","volume":"164","author":"Walker","year":"2019","journal-title":"Arch. Virol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.virusres.2003.12.002","article-title":"The dsRNA viruses","volume":"101","author":"Mertens","year":"2004","journal-title":"Virus Res."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1126\/science.282.5392.1332","article-title":"Reovirus therapy of tumors with activated Ras pathway","volume":"282","author":"Coffey","year":"1998","journal-title":"Science"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10495-006-0528-4","article-title":"Down-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosis","volume":"12","author":"Clarke","year":"2007","journal-title":"Apoptosis"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-1702(03)00045-5","article-title":"Selective reovirus killing of bladder cancer in a co-culture spheroid model","volume":"93","author":"Kilani","year":"2003","journal-title":"Virus Res."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/gutjnl-2016-312009","article-title":"Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer","volume":"67","author":"Samson","year":"2018","journal-title":"Gut"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/0008-5472.CAN-09-2408","article-title":"Oncolytic viral therapy for prostate cancer: Efficacy of reovirus as a biological therapeutic","volume":"70","author":"Thirukkumaran","year":"2010","journal-title":"Cancer Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00280-017-3260-6","article-title":"A phase II study of REOLYSIN(\u00ae) (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma","volume":"79","author":"Mahalingam","year":"2017","journal-title":"Cancer Chemother. Pharm. Ther."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/gt.2012.68","article-title":"Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy","volume":"20","author":"Roulstone","year":"2013","journal-title":"Gene Ther."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1158\/1078-0432.CCR-11-2181","article-title":"Phase I\/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies","volume":"18","author":"Karapanagiotou","year":"2012","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/1078-0432.CCR-10-2159","article-title":"A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer","volume":"17","author":"Lolkema","year":"2011","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_196","first-page":"371","article-title":"Virus combinations and chemotherapy for the treatment of human cancers","volume":"10","author":"Kumar","year":"2008","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40169-018-0214-5","article-title":"Oncolytic viruses and checkpoint inhibitors: Combination therapy in clinical trials","volume":"7","author":"LaRocca","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cytogfr.2010.02.006","article-title":"Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics","volume":"21","author":"Harrington","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_199","first-page":"75","article-title":"Novel therapeutic strategies in human malignancy: Combining immunotherapy and oncolytic virotherapy","volume":"4","author":"Sampath","year":"2015","journal-title":"Oncolytic Virother."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.clcc.2018.03.001","article-title":"A Randomized Phase II Study of FOLFOX6\/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial","volume":"17","author":"Jonker","year":"2018","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/1078-0432.CCR-19-2078","article-title":"Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study","volume":"26","author":"Mahalingam","year":"2020","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"v422","DOI":"10.1093\/annonc\/mdx376.056","article-title":"Pooled data analysis of the safety and tolerability of intravenous pelareorep in combination with chemotherapy in 500 + cancer patients","volume":"28","author":"Gutierrez","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_203","unstructured":"Mehr, S. (2021, May 12). Onco\u2019Zine Editorial Team Positive Top Line Data Presented for Reolysin? in Randomized Phase III Study in Head and Neck Cancers. Available online: https:\/\/www.oncozine.com\/positive-top-line-data-presented-for-reolysin-in-randomized-phase-iii-study-in-head-and-neck-cancers\/."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/gt.2017.95","article-title":"Strategy to detect pre-existing immunity to AAV gene therapy","volume":"24","author":"Falese","year":"2017","journal-title":"Gene Ther."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what\u2019s important?","volume":"10","author":"Kobinger","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1038\/emi.2014.30","article-title":"Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in China","volume":"3","author":"Wang","year":"2014","journal-title":"Emerg. Microbes Infect."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ymthe.2018.01.019","article-title":"Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy","volume":"26","author":"Ricca","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1158\/0008-5472.CAN-19-2062","article-title":"Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy","volume":"80","author":"Feola","year":"2020","journal-title":"Cancer Res."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1038\/s41467-019-11137-5","article-title":"Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy","volume":"10","author":"Niemann","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-019-0515-2","article-title":"Two roads for oncolytic immunotherapy development","volume":"7","author":"Kaufman","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_211","first-page":"555","article-title":"A phase I\/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma","volume":"9","author":"Hecht","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/78638","article-title":"A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer","volume":"6","author":"Khuri","year":"2000","journal-title":"Nat. Med."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/17425247.2019.1617269","article-title":"Achieving systemic delivery of oncolytic viruses","volume":"16","author":"Hill","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"e128217","DOI":"10.1172\/jci.insight.128217","article-title":"Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma","volume":"4","author":"Wirsching","year":"2019","journal-title":"Jci Insight"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/jmv.25501","article-title":"Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma","volume":"91","author":"Kuryk","year":"2019","journal-title":"J. Med. Virol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.omto.2018.10.005","article-title":"Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus","volume":"11","author":"Havunen","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1158\/1078-0432.CCR-16-0477","article-title":"The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model","volume":"23","author":"Li","year":"2017","journal-title":"Clin. Cancer Res. Ther. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1099\/0022-1317-81-11-2605","article-title":"Blood clearance rates of adenovirus type 5 in mice","volume":"81","author":"Alemany","year":"2000","journal-title":"J. Gen. Virol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1128\/JVI.00074-14","article-title":"Vesiculovirus neutralization by natural IgM and complement","volume":"88","author":"Tesfay","year":"2014","journal-title":"J. Virol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"8227","DOI":"10.1073\/pnas.95.14.8227","article-title":"Human parvovirus B19 as a causative agent for rheumatoid arthritis","volume":"95","author":"Takahashi","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00125-018-4561-y","article-title":"Coxsackievirus B1 infections are associated with the initiation of insulin-driven autoimmunity that progresses to type 1 diabetes","volume":"61","author":"Lehtonen","year":"2018","journal-title":"Diabetologia"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: Moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1038\/s41467-020-18828-4","article-title":"Structural characterization of the ICOS\/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies","volume":"11","author":"Rujas","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"e000544","DOI":"10.1136\/esmoopen-2019-000544","article-title":"The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy","volume":"5","author":"Solinas","year":"2020","journal-title":"ESMO Open"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s12032-013-0774-6","article-title":"Granulocyte\u2013macrophage colony-stimulating factor: Not just another haematopoietic growth factor","volume":"31","year":"2014","journal-title":"Med. Oncol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ijc.28696","article-title":"Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans","volume":"135","author":"Bramante","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients with Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S0003-4975(99)00852-8","article-title":"Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system","volume":"68","author":"Lambright","year":"1999","journal-title":"Ann. Thorac. Surg."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"e1512329","DOI":"10.1080\/2162402X.2018.1512329","article-title":"Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials","volume":"8","author":"Pol","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"e10375","DOI":"10.15252\/emmm.201910375","article-title":"Repurposing the yellow fever vaccine for intratumoral immunotherapy","volume":"12","author":"Aznar","year":"2020","journal-title":"Embo Mol. Med."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.ymthe.2020.03.004","article-title":"Safety, Tumor Reduction, and Clinical Impact of Zika Virus Injection in Dogs with Advanced-Stage Brain Tumors","volume":"28","author":"Kaid","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7705\/biomedica.4916","article-title":"Assessing the oncolytic potential of rotavirus on mouse myeloma cell line Sp2\/0-Ag14","volume":"40","author":"Guerrero","year":"2020","journal-title":"Biomedica"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"e000443","DOI":"10.1136\/jitc-2019-000443","article-title":"Repurposing infectious disease vaccines for intratumoral immunotherapy","volume":"8","author":"Melero","year":"2020","journal-title":"J. Immunother. Cancer"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/7\/1271\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:27:12Z","timestamp":1760164032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/7\/1271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":234,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["v13071271"],"URL":"https:\/\/doi.org\/10.3390\/v13071271","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,29]]}}}